The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
复制标题
DOI：
10.1016/j.jtho.2018.07.001
复制
发表时间：
2018-11
期刊：
影响因子：
--
通讯作者：
Doebele RC
中科院分区：
文献类型：
--
作者：
Patil T;Smith DE;Bunn PA;Aisner DL;Le AT;Hancock M;Purcell WT;Bowles DW;Camidge DR;Doebele RC
肺癌的中枢神经系统(CNS)转移是导致发病率和死亡率的常见原因。关于IV期ROS1+非小细胞肺癌(NSCLC)的CNS转移率和克里佐替尼的CNS进展率，有相互矛盾的数据。对2008年6月至2017年12月期间579例IV期非小细胞肺癌患者进行了回顾性研究。记录脑转移和癌基因状态(ROS1、ALK、EGFR、KRAS、BRAF等)。我们测量了服用Crizotinib的ROS1+和ALK+患者的无进展生存期(PFS)和中枢神经系统进展时间(P-CNS)。我们确定了33例ROS1+和115例ALK+的IV期非小细胞肺癌患者。单纯治疗、IV期ROS1+和ALK+NSCLC脑转移发生率分别为36%(12/33)和34%(39/115)。ROS1、ALK、EGFR、KRAS、BRAF或其他突变的脑转移发生率在统计学上没有显著差异。有19名ROS1+和83名ALK+患者的完整生存数据可用。ROS1+和ALK+患者的中位PFS分别为11个月和8个月(p=0.304)。在47%(9/19)的ROS1+和33%(28/83)的ALK+患者中，中枢神经系统是第一个和唯一的进展部位，这两组之间没有差异(p=0.610)。脑转移是常见的治疗-幼稚的IV期ROS1+非小细胞肺癌，尽管其发生率与其他癌基因队列没有什么不同。在服用Crizotinib的ROS1+患者中，中枢神经系统是常见的第一个进展部位。这项研究强调了开发中枢神经系统穿透性TKIs对ROS1+NSCLC患者的重要性。
Central nervous system (CNS) metastases in lung cancer are a frequent cause of morbidity and mortality. There are conflicting data on the incidence of CNS metastases in stage IV ROS1+ non-small cell lung cancer (NSCLC) and rate of CNS progression on crizotinib. A retrospective review of 579 patients with stage IV NSCLC between June 2008 to December 2017 was performed. Brain metastases and oncogene status (ROS1, ALK, EGFR, KRAS, BRAF, and other) were recorded. We measured progression free survival (PFS) and time to CNS progression (P-CNS) in ROS1+ and ALK+ patients on crizotinib. We identified 33 ROS1+ and 115 ALK+ patients with stage IV NSCLC. The incidence of brain metastases for treatment-naïve, stage IV ROS1+ and ALK+ NSCLC was 36% (12/33) and 34% (39/115) respectively. There were no statistically significant differences in incidence of brain metastases across ROS1, ALK, EGFR, KRAS, BRAF or other mutations. Complete survival data was available for 19 ROS1+ and 83 ALK+ patients. Median PFS for ROS1+ and ALK+ patients was 11 and 8 months (p = 0.304). The CNS was the first and sole site of progression in 47% (9/19) of ROS1+ and 33% ALK+ (28/83) patients with no differences between these groups (p = 0.610). Brain metastases are common in treatment-naïve stage IV ROS1+ NSCLC, though the incidence does not differ from other oncogene cohorts. The CNS is a common first site of progression in ROS1+ patients on crizotinib. This study reinforces the importance of developing CNS-penetrant TKIs for patients with ROS1+ NSCLC.
登录
查看更多内容
DOI：
10.1158/1078-0432.ccr-12-0550
发表时间：
2012-09-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Davies KD;Le AT;Theodoro MF;Skokan MC;Aisner DL;Berge EM;Terracciano LM;Cappuzzo F;Incarbone M;Roncalli M;Alloisio M;Santoro A;Camidge DR;Varella-Garcia M;Doebele RC
通讯作者：
Doebele RC
EGFR突变或藻类重新培养的非小细胞肺癌患者的脑转移。
DOI：
10.1016/j.lungcan.2015.01.020
发表时间：
2015-04
期刊：
Lung cancer (Amsterdam, Netherlands)
影响因子：
--
作者：
Rangachari D;Yamaguchi N;VanderLaan PA;Folch E;Mahadevan A;Floyd SR;Uhlmann EJ;Wong ET;Dahlberg SE;Huberman MS;Costa DB
通讯作者：
Costa DB
影响因子：
6.2
作者：
Doebele RC;Lu X;Sumey C;Maxson DA;Weickhardt AJ;Oton AB;Bunn PA Jr;Barón AE;Franklin WA;Aisner DL;Varella-Garcia M;Camidge DR
通讯作者：
Camidge DR
影响因子：
20.4
作者：
Li, Ziming;Shen, Lan;Lu, Shun
通讯作者：
Lu, Shun
影响因子：
45.3
作者：
Kim, Dong-Wan;Tiseo, Marcello;Camidge, D. Ross
通讯作者：
Camidge, D. Ross